Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Eprenetapopt in R/R MCL
NCT04990778Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eprenetapopt in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 16 weeks. Planned start Nov 2021; status: withdrawn.
02
Drugs
eprenetapopt
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04990778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990778.